Next Article in Journal
Clockwise Anterior-to-Posterior—Double Isolation (CAP-DI) Approach for Portal Lymphadenectomy in Biliary Tract Cancer: Technique, Yield, and Outcomes
Next Article in Special Issue
Response to Ovarian Stimulation for Urgent Fertility Preservation before Gonadotoxic Treatment in BRCA-Pathogenic-Variant-Positive Breast Cancer Patients
Previous Article in Journal
Epigenetic Regulation in Chromium-, Nickel- and Cadmium-Induced Carcinogenesis
Previous Article in Special Issue
Oral Contraceptive Use and Breast Cancer Risk for BRCA1 and BRCA2 Mutation Carriers: Systematic Review and Meta-Analysis of Case–Control Studies
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 14
Issue 23
10.3390/cancers14235769
Review Report
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

Should Preimplantation Genetic Testing (PGT) Systematically Be Proposed to BRCA Pathogenic Variant Carriers?

Cancers 2022, 14(23), 5769; https://doi.org/10.3390/cancers14235769
by Lucie Laot 1, Charlotte Sonigo 1,2, Julie Nobre 1, Alexandra Benachi 3, Traicie Dervin 1, Lina El Moujahed 1, Anne Mayeur 4, Dominique Stoppa-Lyonnet 5, Julie Steffann 6 and Michael Grynberg 1,*
Reviewer 1:
Wen-Ling Kuo
Reviewer 2:
Maria C. Katapodi
Cancers 2022, 14(23), 5769; https://doi.org/10.3390/cancers14235769
Submission received: 19 October 2022 / Revised: 16 November 2022 / Accepted: 19 November 2022 / Published: 24 November 2022
(This article belongs to the Special Issue BRCA-Associated Breast Cancer)

Round 1

Reviewer 1 Report

Since 2021, the genetic counseling society has retired the term BRCA "mutation" and changed it to the more neutral term " pathogenic or likely pathogenic variant" to describe a hereditary genetic predisposition to cancer. The attitude should also be carried on in the PGT field as an effort to reduce raising possible ethical and psychological issues. Therefore, I suggest the author do so in this review article to demonstrate your professionalism not only in fertility medicine but also in human genetics.

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 2 Report

This review examines data regarding the usefulness of pre-implantation genetic testing (PGT) among BRCA carriers in order to contribute towards international guidelines regarding the management of fertility preservation in this population.

Overall, the article is well-written and clear. Few comments for improvement:

line 42: edit text ".. aims review to the available..." to "....aims to review available..."

line 78: edit "real life data" to "evidence"

line 86: edit "England" to "UK"

line 132 - 133: (25% if the couple accepts a transfer of male mutated embryos, as it can sometimes be proposed in some countries). The authors should explain why 25% and not 50% if the carrier is male, and provide a reference regarding the countries that this is proposed.

Throughout the manuscript: please avoid the acronym ART and AMH - better to refer to "assisted reproductive techniques" and "anti-Muellerian hormone" every time.

lines 235 and 239: please italicize BRCA

line 256: edit "legit" to "legitimate"

line 260: edit "real life data" to "literature review" or "scientific evidence" or something similar

line 336: please explain "...(including one with sex diagnosis)" What is a sex diagnosis?

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Back to TopTop